HC Wainwright Reiterates Buy Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $400.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 66.31% from the stock’s current price.

ALNY has been the subject of a number of other reports. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Scotiabank upped their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $298.61.

Alnylam Pharmaceuticals Trading Down 6.9 %

ALNY opened at $240.51 on Monday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The business’s 50 day moving average is $248.64 and its two-hundred day moving average is $259.83. The firm has a market cap of $31.02 billion, a price-to-earnings ratio of -91.80 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same quarter last year, the firm earned $1.15 earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% on a year-over-year basis. On average, research analysts predict that Alnylam Pharmaceuticals will post -2.21 EPS for the current year.

Insider Buying and Selling

In related news, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now owns 17,457 shares in the company, valued at approximately $4,381,357.86. This trade represents a 8.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.40. The trade was a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,122 shares of company stock worth $2,540,455 in the last ninety days. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Souders Financial Advisors grew its stake in Alnylam Pharmaceuticals by 1.0% in the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock worth $853,000 after acquiring an additional 36 shares during the period. Huntington National Bank boosted its holdings in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the last quarter. SYM FINANCIAL Corp grew its position in shares of Alnylam Pharmaceuticals by 6.2% in the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 55 shares during the period. Lindbrook Capital LLC grew its position in shares of Alnylam Pharmaceuticals by 11.1% in the third quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 57 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its stake in Alnylam Pharmaceuticals by 0.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company’s stock valued at $1,532,000 after purchasing an additional 58 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.